Daratumumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Daratumumab |
| DrugBank ID | DB09331 |
| Brand Names (EU) | Darzalex |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.13% |
Approved Indication (EMA)
Multiple Myeloma Darzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma. in combination with
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | indolent plasma cell myeloma | 98.13% | DL |
| 2 | plasma cell myeloma | 97.44% | DL |
| 3 | cholangiocarcinoma, susceptibility to | 65.06% | DL |
| 4 | placenta disease | 62.82% | DL |
| 5 | minimally invasive lung adenocarcinoma | 62.75% | DL |
| 6 | GCGR-related hyperglucagonemia | 61.81% | DL |
| 7 | hemoglobin C-beta-thalassemia syndrome | 61.49% | DL |
| 8 | giant cell reparative granuloma | 59.40% | DL |
| 9 | colon inflammatory polyp | 58.73% | DL |
| 10 | dental caries | 58.69% | DL |
| 11 | epidural abscess | 58.08% | DL |
| 12 | prostate adenoid cystic carcinoma | 57.95% | DL |
| 13 | cloacogenic carcinoma | 57.57% | DL |
| 14 | acute articular rheumatism | 57.56% | DL |
| 15 | conduct disorder | 57.44% | DL |
| 16 | intraductal tubulopapillary neoplasm of pancreas | 57.37% | DL |
| 17 | renal artery obstruction | 57.25% | DL |
| 18 | hypercarotenemia and vitamin A deficiency, autosomal recessive | 57.22% | DL |
| 19 | Coronavinae infectious disease | 57.21% | DL |
| 20 | mitral valve stenosis | 57.14% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.